FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

March 23, 2016

CardioComm Solutions’ HeartCheck™ ECG PEN Promoted in USA Today for Cardiovascular Health

Campaign to Continue Building Market Awareness for the HeartCheck™ ECG PEN in the USA

Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global provider of consumer heart monitoring and medical electrocardiogram (“ECG”) device and management software solutions, is pleased to announce their participation in this year’s Cardiovascular Health issue for the American Heart Awareness Campaign that will be released March 25, 2016.

In collaboration with the American College of Cardiology and American Heart Association, CardioComm Solutions’ HeartCheck™ ECG PEN will be promoted in the USA Today based Cardiovascular Health publication. The Campaign itself will serve as a call to action for the millions of Americans living with heart disease to become aware of credible technologies that are available to help them take control of their health. The publication will introduce available innovations in heart monitoring and will carry advertising for the HeartCheck™ ECG PEN.

The HeartCheck™ promotion will have an expected reach of at least 1.3 million readers in the following US cities: New York, Chicago, Washington D.C., San Francisco, Pittsburg/Cleveland, Boston and Seattle.

The Cardiovascular Health publication itself will also be distributed to 19,000 attendees and cardiovascular medical professionals at the 65th American College of Cardiology’s Expo (ACC.16) in Chicago to be held April 4th to 6th and will be featured on the Future of Personal Health website (http://www.futureofpersonalhealth.com/). A separate press release announcing CardioComm Solutions’ sponsorship of the Heart Awareness Campaign will be distributed by the campaign organizers through over 500 of the largest media outlets. CardioComm Solutions has also been quoted in a short editorial in the publication regarding personal medical technologies used in cardiac care.

The HeartCheck™ ECG PEN and free GEMS™ Home software hold FDA clearances as ECG monitoring solutions that can be sold directly to consumers with or without a physician’s prescription therefore making it possible for anyone to take an active role in maintaining their heart health at any time. With respect to physician preference, in addition to the handheld use of the HeartCheck™ device to record an ECG (Lead I), the device can also be held in the right hand and pressed against the left side of the chest, or ribs, to record a Lead II ECG which is better when screening for arrhythmias. Physicians can also recommend the HeartCheck™ devices to their patients and can bill for reviewing the GEMS™ Home generated ECG reports under available third party payer ECG reimbursement codes.

Using the HeartCheck™ device, a 30 second ECG recording can be taken that can confirm the presence or absence of an arrhythmia. Any recorded ECG can be uploaded to CardioComm Solutions’ HIPAA compliant SMART Monitoring ECG reading service to provide an ECG interpretation and report back to HeartCheck™ ECG PEN users. A market advantage of the HeartCheck™ ECG PEN is that it is a small and fully contained ECG device that can independently record, save, replay and transfer recorded ECGs to a computer. The free GEMS™ Home software and SMART Monitoring technologies are based on established ECG software technologies that are currently licensed by the Company to hospitals and clinics across the USA.
To learn more about the CardioComm Solutions’ HeartCheck™ products and to keep informed on new devices that the Company plans to bring to the consumer ECG market please see the Company’s websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.

About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.